Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation.

Breckpot, Karine (Administrative Promotor)
Devoogdt, Nick (Co-Promotor)
D'Huyvetter, Matthias (Co-Promotor)
Keyaerts, Marleen (Co-Promotor)
Ertveldt, Thomas (Mandate)

3 results
- Title
- Start date(ascending)

Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine
Breckpot, K. (Creator) & Ertveldt, T. (Creator), Journal of Nuclear Medicine, 16 Dec 2024
DOI: 10.5281/zenodo/14499964
Dataset
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
Breckpot, K. (Creator) & Ertveldt, T. (Creator), Molecular Cancer Therapy, 16 Dec 2024
DOI: https://doi.org/10.1158/1535-7163.c.6543403.v1
Dataset
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine
Breckpot, K. (Creator) & Ertveldt, T. (Creator), Theranostics, 16 Dec 2024
DOI: 10.5281/zenodo/14500208
Dataset